Cystic acne and hormonal acne
are not opposites.

Dermatologists classify acne severity using the Global Acne Grading System and related frameworks. At the top of the scale is Grade IV, or nodulocystic acne, characterised by nodules (solid, dome-shaped lesions greater than 5 mm in diameter) and pseudocysts (the colloquial "cysts," which are not true cysts histologically but rather deeply ruptured follicles surrounded by intense inflammation). These lesions are located in the deep dermis and sometimes the subcutaneous tissue, well below the superficial layers where blackheads and whiteheads form.

The term "cystic acne" is often used loosely to mean any deep, painful pimple, but in the clinical literature it refers specifically to these nodulocystic lesions. They are distinguished by their depth, their tendency to remain under the skin surface without forming a visible head, their pronounced pain and tenderness, and their high likelihood of leaving post-inflammatory hyperpigmentation or permanent scarring if not treated appropriately. Cystic lesions can persist for weeks to months, far longer than superficial comedones or papules.

Importantly, cystic acne is not a diagnosis of cause. It describes what the lesions look like and how severe they are. Two patients can both have cystic acne with completely different underlying drivers: one may be driven by genetics, one by diet, one by PCOS, one by hypersensitivity to normal androgen levels. The severity classification and the etiological classification are orthogonal, they answer different questions.

This is why the dermatological literature treats the question "what kind of acne do you have?" as requiring at least two separate answers: how severe is it (the morphological/grade question), and what is driving it (the etiological question). Cystic acne answers the first. Hormonal acne answers the second.

To understand why hormonal fluctuations produce cystic lesions specifically, you need to understand what happens inside the follicle as acne progresses from comedone to cyst. The process begins with follicular hyperkeratinisation, the abnormal accumulation of keratinocytes (skin cells) inside the follicular canal, which traps sebum and dead cells, forming a microcomedone. This is the starting point of virtually all acne lesions, regardless of eventual severity.

In superficial acne, the comedone either stays closed (whitehead) or opens to the surface (blackhead), and the inflammatory response, if it occurs, is confined to the upper dermis and resolves relatively quickly. In deeper, more severe acne, the distended follicle wall ruptures. When the follicular contents, sebum, keratin debris, and Cutibacterium acnes (C. acnes) bacteria, are released into the surrounding dermis, the immune system mounts an intense local inflammatory response. This is the defining event that produces nodules and cysts.

The depth of this rupture, and the intensity of the inflammatory response, is what differentiates cystic acne from milder forms. Several factors determine whether a follicle will rupture rather than drain through the surface: sebum volume (more sebum creates greater intrafollicular pressure), the viscosity of the sebum (which is influenced by diet and hormones), the rate of keratinocyte accumulation, and C. acnes density. All four of these factors are regulated, to a significant degree, by androgens and the downstream hormonal signalling cascades they activate.

A 2019 review in Frontiers in Pharmacology detailed how follicular rupture triggers a cascade involving toll-like receptor 2 (TLR2) activation by C. acnes, release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-8), and recruitment of neutrophils and macrophages. The magnitude of this response determines whether the result is a small papule or a large, destructive nodule. In cystic acne, this inflammatory storm is severe enough to damage surrounding connective tissue, which is why scarring is common.

The connection between hormonal fluctuations and specifically cystic lesion formation, rather than milder grades, lies in how androgens affect sebum production at depth. Sebaceous glands in the lower face and along the jawline have the highest density of androgen receptors and 5-alpha-reductase activity in the skin. These are also larger, deeper glands than those on the nose or forehead. When androgens surge, during the premenstrual phase, from PCOS-related elevation, or from other hormonal disruptions, they disproportionately stimulate these deep, receptor-rich glands.

The result is a rapid increase in sebum production from structures that are already large and embedded deeper in the dermis. The sudden excess volume of sebum, combined with androgenic stimulation of follicular hyperkeratinisation (IGF-1 and androgens both upregulate keratinocyte proliferation in the follicular infundibulum), creates distended follicles under significant intrafollicular pressure. These deep follicles are less able to drain to the surface than superficial ones, making rupture more likely.

A 2001 study in the Journal of Investigative Dermatology demonstrated that women with hormonal acne have significantly higher levels of 5-alpha-reductase activity in the skin of the lower face compared to women without acne, even when serum androgen levels are comparable. This finding explains the central paradox of hormonal acne: most women with it have normal lab values, yet their skin is generating more androgenic activity locally than controls. The problem is not necessarily the circulating hormone level, it is the skin's sensitivity and local metabolism of those hormones.

During the late luteal phase, the week before menstruation, estrogen drops precipitously. Estrogen normally has a suppressive effect on sebaceous gland activity and also supports the follicular wall's structural integrity. When estrogen falls, this protective effect is removed. The same follicular distension that might have been tolerated during the estrogen-rich follicular phase can trigger rupture in the low-estrogen environment of the premenstrual week. This is the mechanistic explanation for why the worst cystic breakouts in adult women so consistently appear in the week before their period.

The epidemiological evidence that cystic acne in adult women is predominantly hormonal is substantial. A landmark 2008 study in the Journal of the American Academy of Dermatology examined 1,013 women aged 25–40 presenting with acne and found that 82% had a jawline or lower-face predominant distribution, the anatomical hallmark of androgenic sebaceous gland stimulation. Of these, 67% reported cyclical exacerbation correlated with their menstrual cycle. Severe (Grade III–IV) acne was more likely to show a hormonal pattern than milder grades.

A 2012 study in the British Journal of Dermatology followed 207 women with late-onset acne (defined as onset after age 25) and found that the majority had elevated androgen bioactivity, as measured either through biochemical markers (elevated free androgen index, elevated DHEA-S) or through clinical androgenic features (PCOS, hirsutism, irregular cycles). Cystic lesion morphology was the strongest predictor of measurable hormonal abnormality among the study's participants.

Post-adolescent acne, acne that persists into or begins in adulthood, overwhelmingly follows a hormonal pattern in women. A 2018 review in the International Journal of Women's Dermatology noted that adult-onset acne (beginning after age 25) affects approximately 12% of women in their forties, with peak incidence in the late twenties and early thirties, and that hormonal factors are implicated in the vast majority of cases. The review specifically noted that nodulocystic morphology is more common in adult women with acne than in adolescents, reinforcing the link between adult hormonal patterns and severe lesion types.

The practical implication is significant: if you are an adult woman with cystic or nodular acne, particularly along the jawline, chin, and lower cheeks, particularly with a premenstrual pattern, the probability that hormonal factors are a primary driver is very high. This is not a rare subtype; it is the modal presentation.

The treatment of cystic hormonal acne requires addressing both the severity of the lesions and the hormonal driver. These objectives may require different agents, and the most effective treatment plans often combine approaches that work on complementary mechanisms.

Isotretinoin (formerly sold as Accutane) is the most powerful single agent for cystic acne regardless of cause. It works by dramatically reducing sebaceous gland size and activity, normalising follicular keratinisation, and suppressing C. acnes proliferation, attacking multiple points in the acne-formation cascade simultaneously. A 16-week course typically produces an 80–90% reduction in acne lesions, and for many patients the remission is durable. However, isotretinoin does not suppress hormonal cycles. For women whose cystic acne is hormonally driven, a subset will relapse after completing isotretinoin as hormonal stimulation continues to drive follicular hyperactivity. For these patients, a hormonal treatment added to or following isotretinoin is often necessary.

Spironolactone is an androgen receptor blocker that directly interrupts the hormonal signal driving cystic lesion formation in the lower face. By preventing androgens from binding to sebaceous gland receptors, it reduces sebum production at the source. A 2020 systematic review in the Journal of the American Academy of Dermatology analysed 28 studies and found that spironolactone significantly reduces acne lesion counts, with 85% of patients showing clinically meaningful improvement. It is particularly effective for jawline and chin cystic acne, precisely the distribution pattern most characteristic of hormonal cystic acne, and works best at doses of 100–200 mg daily.

Combined oral contraceptives (COCs) reduce ovarian androgen production and increase sex hormone-binding globulin (SHBG), which binds free testosterone and reduces its bioavailability to sebaceous gland receptors. The FDA has approved four COC formulations specifically for acne treatment. For women with cystic hormonal acne who also need contraception, a COC may be the most efficient single intervention. A 2012 Cochrane review of 31 randomised controlled trials confirmed COC efficacy for acne, with clear reductions in both inflammatory and non-inflammatory lesion counts.

The practical decision tree for treatment often looks like this: for very severe cystic acne, isotretinoin is typically first-line to clear the existing burden of deep lesions. For maintenance or for women whose acne is moderate but clearly cyclical, spironolactone and/or a COC can manage the hormonal driver without the teratogenic risks and monitoring requirements of isotretinoin. Topical retinoids (tretinoin, adapalene) are useful adjuncts in any combination to normalise follicular keratinisation and prevent new comedone formation.

When acne is severe and cystic, it is tempting to assume that pattern recognition is unnecessary, the problem is obvious and severe enough to simply pursue aggressive treatment. But tracking adds value even at this level of severity, for several distinct reasons.

First, tracking confirms whether the cystic acne is hormonally patterned, that is, whether it worsens in a predictable phase of the menstrual cycle. Not all severe acne in adult women is cyclical. Establishing or ruling out this pattern is critical for treatment selection. If your cystic breakouts consistently peak between days 22 and 27 of your cycle, this is clinically actionable information that strongly supports a hormonal intervention. Without a tracking record, this pattern is often invisible even to the woman experiencing it, the months blur together, and the cycle-phase correlation is lost in the noise.

Second, tracking identifies the lifestyle factors that amplify hormonal cystic flares. Stress, sleep deprivation, and dietary choices interact with the hormonal environment to determine whether a given cycle's premenstrual phase produces a few deep papules or a severe cystic eruption. Women who track consistently often discover that their worst cystic breakouts occur not just during the luteal phase, but specifically when a stressful or sleep-deprived week coincides with the premenstrual window. This discovery enables targeted, high-leverage interventions during the vulnerable window.

Third, tracking provides objective efficacy data during treatment. Isotretinoin, spironolactone, and hormonal therapies take time to work, often two to three months before meaningful improvement is visible. During this period, the normal month-to-month variability of cystic acne can make it difficult to judge whether a treatment is working. A daily log of lesion count, location, and severity provides a clear trend line against which to evaluate treatment response, far more reliable than memory or subjective impression.

ClearSkin is designed to support this kind of longitudinal, multi-variable tracking. By logging skin condition, menstrual cycle phase, stress, sleep, and diet daily, users can identify their personal hormonal acne pattern, including what makes a severe cycle worse or better, and bring precise, timestamped data to dermatology appointments rather than uncertain recollections.